RB-601 is a ‘First-in-Man’ Nano Antibody Drug Conjugate targeting tumors expressing c-MET and EGFR.
MET and EGFR are highly expressed in solid tumors
Abnormal MET activation in cancer correlates with poor prognosis, where aberrantly active MET triggers tumor growth and formation of new blood vessels.
EGFR is associated with a number of cancers. Mutations, amplifications or mis-regulations of EGFR or family members are implicated in about 30% of all epithelial cancers.
There is a high level of MET and EGFR co-expression in multiple tumors.
‘Best in Class Potential’:
RB-601 is a ‘First In Man’ Nano Antibody ADC which employs a bispecific nanobody targeting both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition tyrosine kinase receptor (c-MET). Both c-MET and EGFR antibody targets are clinically and market-validated in certain solid tumors.
RB-601 employs site specific conjugation to deliver a homogeneous Drug-to-Antibody Ratio (DAR) of 4 and an innovative, ‘tuned down’ EGFR affinity to enhance the safety profile. When internalized, RB-601 releases monomethyl auristatin E (MMAE) payload which inhibits cell division.
RB-601 demonstrates superior efficacy against a range of human tumors expressing c-MET and EGFR such as lung cancer (NSCLC), colorectal cancer, pancreatic cancer and kidney cancer.
An Investigational New Drug (IND) application for RB-601 (KY-0301) has been cleared by China’s regulatory agency, the National Medical Products Administration (NMPA). RB-601 is currently being investigated by NOVATIM in a Phase 1 dose escalation clinical trial in NSCLC in China. An IND application with the USA Food & Drug Administration (FDA) to execute the clinical development of RB-601 has also been approved. Radiance will be responsible for the clinical development of RB-601 in the US and other licensed territories.
MORE DETAILS CAN BE PROVIDED ON REQUEST